{
    "nct_id": "NCT03264404",
    "official_title": "Phase II Open-Label, Single-Center Study Evaluating Safety and Efficacy of Pembrolizumab Following Induction With the Hypomethylating Agent Azacitidine in Patients With Advanced Pancreatic Cancer After Failure of First-Line Therapy",
    "inclusion_criteria": "* Be willing and able to provide written informed consent for the trial.\n* Age â‰¥18 years of age on day of signing informed consent.\n* Have confirmed diagnosis of pancreatic ductal adenocarcinoma\n* Have a predicted life expectancy of greater than 3 months.\n* Have measurable disease based on RECIST 1.1.\n* Have a performance status of 0 or 1 using the Eastern Cooperative Oncology Group (ECOG) Performance Scale within 3 days of first dose of study drug.\n* Have documented radiographic progression to or documented intolerance of first line systemic chemotherapy which included either gemcitabine or Fluorouracil (5-FU) based regimen (including capecitabine).\n* Subjects who have documented disease recurrence within 6 months of completing neoadjuvant or adjuvant chemotherapy for limited disease will be eligible for study. Subjects who recur greater than 6 months after completing adjuvant or neoadjuvant chemotherapy will not be eligible unless they receive additional chemotherapy for advanced disease.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy, or herbal/complementary oral or IV medicine within 2 weeks of the first dose of treatment.\n* Has received chemotherapy or radiotherapy within 14 days of first dose of study medication.",
    "miscellaneous_criteria": ""
}